eflornithine has been researched along with Keratosis, Actinic in 3 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Keratosis, Actinic: White or pink lesions on the arms, hands, face, or scalp that arise from sun-induced DNA DAMAGE to KERATINOCYTES in exposed areas. They are considered precursor lesions to superficial SQUAMOUS CELL CARCINOMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prevention of nonmelanoma skin cancers remains a health priority due to high costs associated with this disease." | 2.82 | Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. ( Alberts, DS; Bartels, HG; Bartels, P; Bermudez, Y; Curiel-Lewandrowski, C; Einspahr, JG; Hu, C; Jeter, JM; Myrdal, PB; Stratton, SP; Warneke, JA; Yozwiak, M, 2016) |
| "With the incidence of nonmelanoma skin cancer on the rise, current prevention methods, such as the use of sunscreens, have yet to prove adequate to reverse this trend." | 1.37 | New agents for prevention of ultraviolet-induced nonmelanoma skin cancer. ( Athar, M; Camp, WL; Elmets, CA; Turnham, JW, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeter, JM | 1 |
| Curiel-Lewandrowski, C | 1 |
| Stratton, SP | 1 |
| Myrdal, PB | 1 |
| Warneke, JA | 1 |
| Einspahr, JG | 1 |
| Bartels, HG | 1 |
| Yozwiak, M | 2 |
| Bermudez, Y | 1 |
| Hu, C | 1 |
| Bartels, P | 2 |
| Alberts, DS | 2 |
| Einspahr, J | 1 |
| Saboda, K | 1 |
| Liu, Y | 1 |
| Brooks, C | 1 |
| Bartels, H | 1 |
| Camp, WL | 1 |
| Turnham, JW | 1 |
| Athar, M | 1 |
| Elmets, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm[NCT00601640] | Phase 2 | 184 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage. (NCT00601640)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.33 |
| Diclofenac Sodium | 0.26 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.64 |
Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant. (NCT00601640)
Timeframe: 3 months
| Intervention | nmol/g skin (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.03 |
| Diclofenac Sodium | 1.45 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.2 |
Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up. (NCT00601640)
Timeframe: 3 months
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burning and Stinging None | Burning and stinging Mild | burning and stinging Moderate | Burning and Stinging Severe | Pruritis None | Pruritis Mild | Pruritis Moderate | Pruritis Severe | Rash, Redness. Erythema-None | Rash, Redness. Erythema-Mild | Rash, Redness. Erythema-Moderate | Rash, Redness. Erythema-Severe | |
| Diclofenac Sodium | 44 | 8 | 0 | 0 | 33 | 12 | 6 | 1 | 34 | 10 | 8 | 0 |
| Eflornithine Hydrochloride | 48 | 4 | 0 | 0 | 42 | 9 | 1 | 0 | 46 | 5 | 1 | 0 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 48 | 3 | 1 | 0 | 40 | 6 | 6 | 0 | 40 | 7 | 5 | 0 |
2 trials available for eflornithine and Keratosis, Actinic
| Article | Year |
|---|---|
Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Di | 2016 |
Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Cell Nucleus; Dose-Response Relationship, Drug | 2009 |
1 other study available for eflornithine and Keratosis, Actinic
| Article | Year |
|---|---|
New agents for prevention of ultraviolet-induced nonmelanoma skin cancer.
Topics: Anilides; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Carotenoids; Cell Transformation, Neoplas | 2011 |